

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Brii Biosciences Limited
騰盛博藥生物科技有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2137)

**DELAY IN DESPATCH OF CIRCULAR IN RESPECT OF
CONNECTED TRANSACTIONS IN RELATION TO PROPOSED GRANTS OF
RESTRICTED SHARE UNITS TO EXECUTIVE DIRECTORS**

Reference is made to the announcement of Brii Biosciences Limited (the “**Company**”) dated January 20, 2022 in relation to the Proposed RSU Grants to EDs (the “**Announcement**”). Unless the context otherwise requires, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcement.

As disclosed in the Announcement, a circular containing, among other things, (i) further details of the Proposed RSU Grants to EDs; (ii) a letter from the Independent Board Committee; and (iii) a letter from the Independent Financial Advisor, together with the notice convening the EGM, is expected to be despatched to the Shareholders on or before February 15, 2022. As additional time is required to prepare and finalize certain information to be included in the circular, it is expected that the despatch date of the circular will be postponed to a date falling on or before March 8, 2022.

By order of the Board
Brii Biosciences Limited
Dr. Zhi Hong
Chairman

Hong Kong, February 15, 2022

As at the date of this announcement, the Board comprises Dr. Zhi Hong and Mr. Yongqing Luo as executive Directors; Mr. Robert Taylor Nelsen and Dr. Axel Bouchon as non-executive Directors; and Dr. Martin J Murphy Jr, Ms. Grace Hui Tang, Mr. Yiu Wa Alec Tsui and Mr. Gregg Huber Alton as independent non-executive Directors.